The agreement states that Orbit will implement its bead-based peptide display engine to discover peptide leads specific to targets related to specific tumors. Orano Med and Orbit Discovery announced ...
PLANO, Texas & OXFORD, England--(BUSINESS WIRE)--Orano Med SAS, “Orano Med”, a biotechnology company developing Lead-212 (212 Pb) Targeted Alpha Therapy against cancer, and Orbit Discovery Ltd, “Orbit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback